Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Urologic Neoplasms
15. October 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 9109
Articles 1 - 20 / 182176
Real-World Comparative Effectiveness of Lobaplatin Versus Epirubicin and Gemcitabine for Post-TURBT Intravesical Therapy in Non-Muscle-Invasive Bladder Cancer.
Arch Esp Urol
Han S, Li X, Ma L, Hu Z, Jia Z, Wu M, Xing N.
PMID: 42876134 [PubMed - indexed for MEDLINE]
Metabolic Syndrome and Bladder Cancer Risk: A Meta-Analysis of Cohort Studies.
Arch Esp Urol
Teng H, Chen J, Qian J, Chen L, Zhu Y, Tang T, Wang P, Xu X.
PMID: 42876132 [PubMed - indexed for MEDLINE]
Diagnostic Value of Conventional Ultrasound Combined With Contrast-Enhanced Ultrasound for Differentiating Small Clear Cell and Non-Clear Cell Renal Cell Carcinomas.
Arch Esp Urol
Zhao J, Xia Y.
PMID: 42876128 [PubMed - indexed for MEDLINE]
Diagnostic Value of Artificial Intelligence-Based Multiparametric MRI for Prostate Cancer in Patients With PSA Levels in the Gray Zone.
Arch Esp Urol
Mei B, Zhu L, Li Y, Mao X, Dong G.
PMID: 42876127 [PubMed - indexed for MEDLINE]
Evaluation of online dose-guided adaptive fractionation for intact prostate radiotherapy.
J Appl Clin Med Phys
Gevorkyan GS, Zhu L, Tegtmeier RC, Santos Toesca D, Lu W, Chen M, Rong Y, Chen Q.
PMID: 42875902 [PubMed - indexed for MEDLINE]
Metabolic and oncological effects of metformin added to ADT in prostate cancer: systematic review and meta-analysis including STAMPEDE.
Prostate Cancer Prostatic Dis
Fakhri F, Alkhairi Z, Sarhan T, Imran G, Imran L, Moola R, Darwish R, Al-Majmuei A.
PMID: 42875601 [PubMed - as supplied by publisher]
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial.
Nat Med
Zacchi F, Castro E, Imbach K, Rodriguez-Vida A, Simonetti S, Mellado B, Mir Arnau G, Aguilar D, Castellano D, Climent MA, Ramos MJ, Borque-Fernando A, Guerrero JA, Gonzalez-Alonso P, Perez-Escuredo J, Izquierdo V, Saez MI, Domenech H, Arce-Gallego S, Herrera-Imbroda B, Planas J, Lorente D, Font A, Oliveira A, Cresta Morgado P, Esquefa V, Brandariz J, Anselmino N, Zhu K, Troncoso P, Aguilera M, Vivancos A, Nuciforo P, Casanova-Salas I, Porta E, Carles J, Zurita AJ, Mateo J.
PMID: 42875559 [PubMed - as supplied by publisher]
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study.
Clin Genitourin Cancer
Kalebasty AR, Sun J, Tombal B, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Littleton N, Verholen F, Zhang W, Ploeger B, Li R, Zieschang C, Smith MR.
PMID: 42875365 [PubMed - as supplied by publisher]
Aberrant HER2 Expression as a Specific and Feasible Diagnostic Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Hum Pathol
Hu J, Zhang M, Meng L, Zheng L, Yang Y, Tang J, Pan X, Yin X, Yu T, Nie L, Wei Y, Zhou Q, Chen X, Chen N.
PMID: 42874879 [PubMed - as supplied by publisher]
Periprostatic adipose tissue imaging in prostate cancer: Imaging phenotypes, task-specific spatial strategies, and multicompartment integration-a critical review.
Eur J Radiol
Huang J, Zhang Y, Yang O, Feng Q, Du H, Gong J, Huang G.
PMID: 42874220 [PubMed - as supplied by publisher]
PANoptosis-Related Molecular Subtyping and a Subtype-Derived Prognostic Signature for Survival Prediction in Clear Cell Renal Cell Carcinoma.
Technol Cancer Res Treat
Wang X, Shen Y, Du S, Wang H, Xie X, He H.
PMID: 42874083 [PubMed - indexed for MEDLINE]
Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial.
J Clin Oncol
Solanki AA, Adams W, Proudfoot JA, Baldea K, Barkan GA, Block AM, Desai NB, Farooq A, Folkert MR, Garant A, Gorbonos A, Gupta G, Kang H, Kelly E, Kregel S, Liauw SL, Luminais CK, Mysz M, Quek ML, Showalter TN, Welsh JS, Woods M, Davicioni E, Small W Jr, Harkenrider MM.
PMID: 42874014 [PubMed - as supplied by publisher]
Educational disparities in prostate cancer survival: a retrospective cohort study from Mexico City.
Salud Publica Mex
Hernández-Pérez JG, Reyes-Morales H, Valenzuela-Sánchez A, Lajous M, Rodríguez-Covarrubias F, Espin-Arellano LI, Morales-Carmona E, Manzanilla-García H, Torres-Sánchez LE.
PMID: 42873951 [PubMed - indexed for MEDLINE]
Dehydrated human amniotic membrane for early return of erectile function after robotic radical prostatectomy: a 10-year journey and lessons learned.
J Robot Surg
Razdan S, Fathollahi A, Armache A, Razdan S.
PMID: 42873363 [PubMed - indexed for MEDLINE]
Skin-Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real-World Database Study (A Retrospective Cohort Study).
Health Sci Rep
Hashizume A, Kawahara T, Yamazaki M, Takamoto D, Takeshima T, Kuroda S, Uemura H, Makiyama K, Teranishi JI.
PMID: 42871337 [PubMed]
Omission of lateral isocenter shifts in robust optimization of proton therapy treatment plans for prostate cancer.
J Appl Clin Med Phys
O'Grady FT, Castro J, Kim DW, Fan J, Wang P.
PMID: 42870582 [PubMed - indexed for MEDLINE]
Prostate Cancer Therapy via Inhibition of Negative Immune Regulation.
Biomed Res Int
Dutta S, Sengupta P, Chowdhury U, Maldonado Rosas I, Kalita JC, Selvam MKP, Roychoudhury S.
PMID: 42870457 [PubMed - indexed for MEDLINE]
Liquid biopsy in bladder cancer: towards precision oncology.
J Transl Med
Chen C, Yang Y, Chen Z, Li X, Zhu Y, Zhai Y, Zheng J, Dai X, Zhou JG, Ma H, Ye X.
PMID: 42870280 [PubMed - indexed for MEDLINE]
Reproducibility and diagnostic performance of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: a multi-ROI comparison analysis from the phase-Ib NABUCCO trial.
Insights Imaging
Greidanus J, Bernabei C, Chupetvloska K, Agrotis G, Mertens LS, van Rhijn BWG, van der Poel HG, van der Heijden MS, Beets-Tan RGH, Pizzi AD, Boellaard TN, Trebeschi S.
PMID: 42870138 [PubMed]
Fracture risk and fracture risk factor assessment among men at prostate cancer diagnosis.
Prostate Cancer Prostatic Dis
Shulman MJ, Darbinian JA, Chandra M, Harzstark AL, Lo JC.
PMID: 42869964 [PubMed - as supplied by publisher]
Articles 1 - 20 / 182176
Page 1 of 9109
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy